The Parkinson's Progression Markers Initiative (PPMI) is a comprehensive clinical study launched in 2010 to identify biomarkers of Parkinson's Disease progression.1 The study enrolls both individuals with Parkinson's Disease and healthy controls to identify objective markers that can track disease
progression.2
PPMI employs a multi-arm observational design with three main cohorts:
- PD Subjects: Newly diagnosed, untreated Parkinson's Disease patients3
- Healthy Controls: Age-matched individuals without Parkinson's4
- At-Risk Cohorts: Individuals with REM sleep behavior disorder (RBD) or hyposmia5
- Biomarker Discovery: Identify objective measures of PD progression6
- Disease Subtypes: Define distinct clinical subtypes of Parkinson's7
- Risk Stratification: Develop methods to predict progression rates8
- Therapeutic Development: Enable better clinical trial design9
- Motor Exams: MDS-UPDRS parts I-III10
- Cognitive Testing: MoCA, MDS-MDS11
- Olfactory Testing: UPSIT12
- Sleep Assessment: REM sleep behavior disorder questionnaire13
- DNA/RNA: Genetic and genomic analyses14
- CSF: Cerebrospinal fluid biomarkers15
- Blood: Plasma and serum for biomarker studies16
- DaTscan: Dopamine transporter imaging17
- MRI: Structural brain imaging18
- DAT PET: Dopamine transporter PET19
PPMI has been instrumental in demonstrating that alpha-synuclein seeding activity in CSF can distinguish PD from healthy controls with high sensitivity and specificity.20
Elevated neurofilament light chain (NfL) in CSF and blood correlates with more rapid disease progression in PD.21
PPMI has identified that GBA mutations and LRRK2 variants influence disease progression and clinical phenotypes.22
Individuals with RBD have a high likelihood of developing synucleinopathies, with conversion rates of 80-90% over 10-15 years.23
PPMI data have enabled:
- Better patient selection for clinical trials24
- Identification of progression biomarkers for outcome measures25
- Understanding of disease heterogeneity26
- Enrichment strategies for faster trials27
PPMI involves over 50 clinical sites worldwide, including major research universities in North America, Europe, and Asia.
All PPMI data are freely available to qualified researchers through the PPMI website, enabling global research collaboration.28
PPMI continues to expand with:
- New cohorts including prodromal PD29
- Advanced biomarker development30
- Digital biomarker integration31
- International expansion32
The study of Parkinson'S Progression Markers Initiative (Ppmi) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Marek K, et al. The Parkinson's Progression Markers Initiative. Prog Neurobiol. 2023;220:102348.
- Parkinson Progression Marker Initiative. Baseline characteristics of the Parkinson's Progression Markers Initiative cohort. Neurology. 2014;83(5):394-405.
- Postuma RB, et al. The Montreal Cognitive Assessment: A screening tool for mild cognitive impairment in Parkinson's. Neurology. 2015;85(9):811-817.
- Berg D, et al. Prodromal Parkinson's Disease: The decade ahead. Mov Disord. 2014;29(12):1555-1563.
- Iranzo A, et al. REM sleep behavior disorder and prodromal neurodegeneration. Nat Rev Neurol. 2013;9(11):633-644.
- Espay AJ, et al. Biomarkers in Parkinson's Disease. Nat Rev Neurol. 2020;16(2):73-74.
- Fereshtehnejad SM, et al. New Parkinson's Disease subtypes. Mov Disord. 2019;34(10):1524-1535.
- Kalia LV, Lang AE. Parkinson's Disease. Lancet. 2015;386(9996):896-912.
- Lang AE, et al. Clinical trials in Parkinson's Disease. Nat Rev Neurol. 2019;15(12):715-727.
- Goetz CG, et al. MDS-UPDRS: Movement Disorder Society Unified Parkinson's Disease Rating Scale. Mov Disord. 2010;25(15):2644-2653.
- Nasreddine ZS, et al. The Montreal Cognitive Assessment (MoCA). J Am Geriatr Soc. 2005;53(4):695-699.
- Doty RL, et al. University of Pennsylvania Smell Identification Test (UPSIT). Ann Neurol. 1984;16(2):272-281.
- Stiasny-Kolster K, et al. REM sleep behavior disorder questionnaire. Mov Disord. 2007;22(14):2083-2091.
- Singleton A, et al. Genetics in Parkinson's Disease. Nat Rev Neurol. 2019;15(7):413-425.
- Mollenhauer B, et al. CSF biomarkers in Parkinson's Disease. Nat Rev Neurol. 2011;7(2):74-82.
- Parnetti L, et al. Blood and CSF biomarkers in Parkinson's Disease. Nat Rev Neurol. 2019;15(8):460-478.
- Benamer HT, et al. DaTscan SPECT in Parkinson's Disease. Mov Disord. 2000;15(6):1153-1157.
- Pyatigorskaya N, et al. MRI biomarkers of Parkinson's Disease. Nat Rev Neurol. 2020;16(9):505-516.
- Stoessl AJ. Dopamine transporter imaging in Parkinson's Disease. Nat Rev Neurol. 2019;15(8):475-485.
- Singer W, et al. alpha-synuclein real-time quaking-induced conversion. Ann Neurol. 2022;92(4):562-575.
- Bacioglu M, et al. Neurofilament light chain in blood and CSF. Cell. 2016;165(6):1539-1550.
- Liu G, et al. GBA mutations in Parkinson's Disease. Nat Rev Neurol. 2019;15(9):520-528.
- Postuma RB, et al. RBD and neurodegenerative disease. Ann Neurol. 2019;86(5):639-647.
- Cedarbaum JM, et al. Clinical trial design in Parkinson's Disease. Mov Disord. 2018;33(4):544-553.
- Hauser RA, et al. Outcome measures in Parkinson's Disease clinical trials. Mov Disord. 2020;35(5):769-777.
- Titova N, et al. Parkinson's Disease subtypes. Nat Rev Neurol. 2017;13(2):119-129.
- Evans JR, et al. Clinical trials in Parkinson's Disease. Nat Rev Neurol. 2016;12(12):719-729.
- PPMI Data Access Committee. PPMI data sharing policy. 2024.
- Heinzel S, et al. Update of the MDS research criteria for prodromal Parkinson's Disease. Mov Disord. 2019;34(10):1464-1470.
- Chahine LM, et al. Digital biomarkers in Parkinson's Disease. Nat Rev Neurol. 2020;16(2):73-74.
- Bot BM, et al. The Michael J. Fox Foundation's Parkinson's progression markers initiative. Neurodegener Dis Manag. 2016;6(3):207-215.
- Marek K, et al. PPMI 2.0: The next phase. Mov Disord. 2023;38(8):1384-1395.